Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep correction. Lilly is by no means in bad shape, but because the stock's price has become so inflated in recent years, so have expectations.
Eli Lilly & Co. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top
We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Brown plays the Princeton Tigers after Kino Lilly Jr. scored 34 points in the Bears' 88-79 win against the Pennsylvania Quakers.
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
PHILADELPHIA (AP) — Kino Lilly Jr. scored 34 points and made eight 3-pointers as Brown beat Pennsylvania 88-79 on Friday night.
We catch up with the stellar singer-songwriter about the process of grounding herself that led to making her sixth album.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
Leerink notes Eli Lilly (LLY) terminated its volenrelaxin CKD due to failure of a “related heart failure study,” which has caused significant ...
Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with the ...
CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week, highlighting reports from Amazon, Alphabet, Eli Lilly and Palantir, as well as a key inflation metric from the Labor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback